Positive effect of HPV status on prognostic value of blood lymphocyte-to-monocyte ratio in advanced cervical carcinoma

Table 1 Correlation of pretreatment LMR with clinicopathologic characteristics of patients with advanced cervical carcinoma (n = 424)

Characteristic	No. of patients (%)	Pretreatment LMR level		p value	HPV DNA status		p value
Characteristic	No. of patients (%)	High value (n = 260)	Low value (n = 164)	p value	HR-positive (n = 390)	Non-HR (n = 34)	p value
Age, years
≤46	205 (48.35 %)	133	72	0.146	190	15	0.607
>46	219 (51.65 %)	127	92		200	19	0.607
HPV DNA
Positive	390 (91.98 %)	246	144	0.012	–	–	–
Negative	34 (8.02 %)	14	20		–	–
Lymph node status classification
Node-negative	277 (65.33 %)	212	65	0.001	252	25	0.295
Node-positive	147 (34.67 %)	48	99		138	9	0.295
FIGO classification
IIA	86 (20.28 %)	41	45	0.0 22	81	5	0.803
IIB	84 (19. 81 %)	48	36		78	6
IIIA	92 (21.70 %)	63	29		83	9
IIIB	90 (21.23 %)	61	29		81	9
IVA	72 (16.98 %)	47	25		67	5
Pathological type
SCC	305 (71.93 %)	194	111	0.337	288	17	0.016
ADC	31 (7.31 %)	19	12		25	6
ASC	33 (7.78 %)	19	14		29	4
UDC	55 (12.97 %)	28	27		48	7
Treatment modality
IC + RT	143 (33.73 %)	83	60	0.607	132	11	0.984
CCRT	147 (34.67 %)	92	55		135	12
IC + CCRT	134 (31.60 %)	85	49		123	11

LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; SCC squamous cell carcinoma; Ag antigen; FIGO International Federation of Gynecology and Obstetrics; ADC adenocarcinoma; ASC adenosquamous carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; HR high risk

ISSN: 1475-2867